OBJECTIVE: The aim of this study was to assess the effectiveness and tolerability of a long-acting methylphenidate (MPH) formulation, beaded MPH (B-MPH), for treatment of attention-deficit/hyperactivity disorder (ADHD) in 4- and 5-year-old children. METHOD: Eleven children (9 boys and 2 girls) with ADHD received 4 weeks of B-MPH treatment in a single-site, open-label pilot study. Medication dosing was flexible, with titration to a maximum of 30 mg/day. A brief education session on behavior management was offered to parents at each treatment visit. RESULTS: Subjects experienced a mean decrease of 1.09 (standard deviation [SD]=0.73, p<0.01) on the Swanson, Nolan, and Pelham Questionnaire (SNAP-IV) ADHD composite score to an end point of 1.18 (SD=0.64). Subjects demonstrated mean decreases in scores of inattention of 1.01 (SD=0.85, p<0.01) and in hyperactivity/impulsivity of 1.17 (SD=0.74, p<0.01), with end point scores of 1.10 (SD=0.61) and 1.26 (SD=0.77), respectively. The Clinical Global Impressions-Severity (CGI-S) scale showed a statistically significant improvement from a baseline mean of 5 to the final visit mean of 3.36 (p<0.01). At the final visit, the mean daily B-MPH dose was 17.73 mg. Subjects did not experience any statistically significant changes in weight, blood pressure, or pulse during the study. The most common adverse event was decreased appetite. CONCLUSION: B-MPH was safe and effective for the treatment of ADHD in the 4- and 5-year-olds participating in this study.
OBJECTIVE: The aim of this study was to assess the effectiveness and tolerability of a long-acting methylphenidate (MPH) formulation, beaded MPH (B-MPH), for treatment of attention-deficit/hyperactivity disorder (ADHD) in 4- and 5-year-old children. METHOD: Eleven children (9 boys and 2 girls) with ADHD received 4 weeks of B-MPH treatment in a single-site, open-label pilot study. Medication dosing was flexible, with titration to a maximum of 30 mg/day. A brief education session on behavior management was offered to parents at each treatment visit. RESULTS: Subjects experienced a mean decrease of 1.09 (standard deviation [SD]=0.73, p<0.01) on the Swanson, Nolan, and Pelham Questionnaire (SNAP-IV) ADHD composite score to an end point of 1.18 (SD=0.64). Subjects demonstrated mean decreases in scores of inattention of 1.01 (SD=0.85, p<0.01) and in hyperactivity/impulsivity of 1.17 (SD=0.74, p<0.01), with end point scores of 1.10 (SD=0.61) and 1.26 (SD=0.77), respectively. The Clinical Global Impressions-Severity (CGI-S) scale showed a statistically significant improvement from a baseline mean of 5 to the final visit mean of 3.36 (p<0.01). At the final visit, the mean daily B-MPH dose was 17.73 mg. Subjects did not experience any statistically significant changes in weight, blood pressure, or pulse during the study. The most common adverse event was decreased appetite. CONCLUSION: B-MPH was safe and effective for the treatment of ADHD in the 4- and 5-year-olds participating in this study.
Authors: Laurence Greenhill; Scott Kollins; Howard Abikoff; James McCracken; Mark Riddle; James Swanson; James McGough; Sharon Wigal; Tim Wigal; Benedetto Vitiello; Anne Skrobala; Kelly Posner; Jaswinder Ghuman; Charles Cunningham; Mark Davies; Shirley Chuang; Tom Cooper Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-11 Impact factor: 8.829
Authors: Scott Kollins; Laurence Greenhill; James Swanson; Sharon Wigal; Howard Abikoff; James McCRACKEN; Mark Riddle; James McGOUGH; Benedetto Vitiello; Tim Wigal; Anne Skrobala; Kelly Posner; Jaswinder Ghuman; Mark Davies; Charles Cunningham; Audrey Bauzo Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-11 Impact factor: 8.829
Authors: Tim Wigal; Laurence Greenhill; Shirley Chuang; James McGOUGH; Benedetto Vitiello; Anne Skrobala; James Swanson; Sharon Wigal; Howard Abikoff; Scott Kollins; James McCRACKEN; Mark Riddle; Kelly Posner; Jaswinder Ghuman; Mark Davies; Ben Thorp; Annamarie Stehli Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-11 Impact factor: 8.829
Authors: Christopher J Kratochvil; Brigette S Vaughan; Michelle L Mayfield-Jorgensen; John S March; Scott H Kollins; Desiree W Murray; Hima Ravi; Laurence L Greenhill; Lisa A Kotler; Natalya Paykina; Patricia Biggins; Julie Stoner Journal: J Child Adolesc Psychopharmacol Date: 2007-04 Impact factor: 2.576
Authors: Benedetto Vitiello; Howard B Abikoff; Shirley Z Chuang; Scott H Kollins; James T McCracken; Mark A Riddle; James M Swanson; Tim Wigal; James J McGough; Jaswinder K Ghuman; Sharon B Wigal; Anne M Skrobala; Mark Davies; Kelly Posner; Charles Cunningham; Laurence L Greenhill Journal: J Child Adolesc Psychopharmacol Date: 2007-10 Impact factor: 2.576
Authors: Edmund J S Sonuga-Barke; James M Swanson; David Coghill; Heleen H DeCory; Simon J Hatch Journal: BMC Psychiatry Date: 2004-09-30 Impact factor: 3.630
Authors: J R Valdizán-Usón; A Cánovas-Martínez; M T De Lucas-Taracena; F Díaz-Atienza; L S Eddy-Ives; A Fernández-Jaén; M Fernández-Pérez; M García-Giral; P García-Magán; M Garraus-Oneca; M A Idiazábal-Alecha; M López-Benito; G Lorenzo-Sanz; J Martínez-Antón; M A Martínez-Granero; F Montañés-Rada; F Mulas-Delgado; G Ochando-Perales; E Ortega-García; A Pelaz-Antolín; J A Ramos-Quiroga; F C Ruiz-Sanz; J Vaquerizo-Madrid; A Yusta-Izquierdo Journal: Neuropsychiatr Dis Treat Date: 2013-02-08 Impact factor: 2.570
Authors: Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2018-05-09